{"symbol": "UROV", "name": "Urovant Sciences", "next_earnings_utc": 1591906500, "next_earnings_period_start_date_utc": 1577750400, "next_earnings_period_end_date_utc": 1585612800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -1.36092, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "urovant.com", "year_founded": 2016, "street_address": "11-12 Street, James\u00e2\u20ac\u2122s Square", "city": "London", "state": null, "zipcode": "SW1Y 4LB", "country": "United Kingdom", "phone_number": "44 20 7400 3347", "short_description": "Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions.", "long_description": "Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. The company is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.\r\n", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 300316357, "total_enterprise": 302956357, "number_of_employees": 39, "outstanding_shares": 30519955, "eps": -4.103155, "diluted_eps": -4.103155, "earnings_from_cont_operations": -124453000, "gross_profit": null, "cash": 131921000, "total_debt": 134561000, "total_revenue": null, "cash_from_operations": -94502000, "net_income": -124453000, "ebitda": -121095000, "year_low_stock_price": 6.55, "year_high_stock_price": 15.98, "seekingalpha_follower_count": 794, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/UROV.png"}